(NASDAQ: CDXS) CODEXIS's forecast annual revenue growth rate of 20.38% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 18.28%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 9.27%.
CODEXIS's revenue in 2022 is $122,063,000.On average, 5 Wall Street analysts forecast CDXS's revenue for 2022 to be $10,116,382,543, with the lowest CDXS revenue forecast at $9,998,051,586, and the highest CDXS revenue forecast at $10,297,797,221. On average, 5 Wall Street analysts forecast CDXS's revenue for 2023 to be $11,333,127,789, with the lowest CDXS revenue forecast at $9,998,051,586, and the highest CDXS revenue forecast at $12,304,590,985.
In 2024, CDXS is forecast to generate $14,355,138,469 in revenue, with the lowest revenue forecast at $10,507,423,254 and the highest revenue forecast at $18,908,137,532.